Recently, PD-L1 immune checkpoint inhibitor antibodies in multiple clinical trials were used to treat many cancer types [4–9], including melanoma, non-small cell lung cancer (NSCLC), hepatocellular carcinoma, esophageal cancer and bladder cancer. Here, CD274 is linked to non-small cell lung carcinoma.